PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Marayati, Raoud, Stafman, Laura L., Williams, Adele P., Bownes, Laura V., Quinn, Colin H., Aye, Jamie M., Stewart, Jerry E., Yoon, Karina J., Anderson, Joshua C., Willey, Christopher D., Beierle, Elizabeth A.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://ncbi.nlm.nih.gov/pubmed/33727604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85289-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires